Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR

FASENRA® is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.

FASENRA® (benralizumab injection) offers a convenient dosing schedule1

dose-scheduledose-schedule

Flexible administration options for you and your patients1

Home icon

AT-HOME ADMINISTRATION

A patient may self-inject, or the patient’s caregiver may administer FASENRA® after the healthcare professional determines it is appropriate.

The Connect360° Patient Support Program can provide training for patients and caregivers injecting FASENRA®.

The Connect360° Patient Support Program can provide training for patients and caregivers injecting FASENRA®.

Doctor icon

IN-CLINIC ADMINISTRATION

FASENRA® can be administered at any Connect360º Patient Support Program clinic or your office.

FASENRA® is for subcutaneous use only. FASENRA® should be initiated by a qualified healthcare professional experienced in diagnosing and treating severe asthma, with medical follow-up as necessary. Administration by patients or caregivers should only be considered after proper injection training, demonstrated proficiency, and education on signs and symptoms of hypersensitivity reactions.1

Refer to Product Monograph for complete dosing and administration information.

Talk to your patients about which administration option is most convenient for them

  • FASENRA PEN™

    FASENRA PEN™

  • FASENRA® prefilled syringe

    FASENRA® prefilled syringe

  • FASENRA PEN™

    FASENRA PEN™

  • FASENRA® prefilled syringe

    FASENRA® prefilled syringe

(not actual size)

Comparison of dose frequency for severe eosinophilic asthma treatments1-5

dose-frequency dose-frequency

Adapted from individual Product Monographs. See respective Product Monographs for complete dosing and administration information.
Comparative clinical significance unknown.

FASENRA® offers a dosing schedule with the fewest injections per year.*

All trademarks are the property of their respective owners.

* Comparative clinical significance unknown.

Q2W: every other week; Q4W: every 4 weeks; Q8W: every 8 weeks; SC: subcutaneous.

References:

  1. FASENRA® Product Monograph, AstraZeneca Canada Inc.
  2. NUCALA® Product Monograph, GlaxoSmithKline Inc.
  3. CINQAIRTM Product Monograph, Teva Canada Ltd.
  4. DUPIXENT® Product Monograph, Sanofi-aventis Canada Inc.
  5. TEZSPIRE® Product Monograph, AstraZeneca Canada Inc.